Drishti Rathod - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2019	2
2020	1
2022	0

Page 1

Protein kinase C inhibitor anchored BRD4 PROTAC PEGylated nanoliposomes for the treatment of vemurafenib-resistant melanoma.

Fu Y, Rathod D, Patel K. Fu Y, et al. Among authors: rathod d. Exp Cell Res. 2020 Nov 1;396(1):112275. doi: 10.1016/j.yexcr.2020.112275. Epub 2020 Sep 6. Exp Cell Res. 2020. PMID: 32898554

EphA2-Receptor Targeted PEGylated Nanoliposomes for the Treatment of BRAF^V600E Mutated Parent- and Vemurafenib-Resistant Melanoma.

Fu Y, Rathod D, Abo-Ali EM, Dukhande VV, Patel K. Fu Y, et al. Among authors: rathod d. Pharmaceutics. 2019 Oct 1;11(10):504. doi: 10.3390/pharmaceutics11100504. Pharmaceutics. 2019. PMID: 31581483 Free PMC article.

BRD4 PROTAC as a novel therapeutic approach for the treatment of vemurafenib resistant melanoma: Preformulation studies, formulation development and in vitro evaluation.

Rathod D, Fu Y, Patel K. Rathod D, et al. Eur J Pharm Sci. 2019 Oct 1;138:105039. doi: 10.1016/j.ejps.2019.105039. Epub 2019 Aug 5. Eur J Pharm Sci. 2019. PMID: 31394259

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results